Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ROIV Roivant Sciences Ltd.

Closed 04-01 16:00:00 EDT

9.85

-0.24

-2.38%

盘后9.85

+0.000.00%

18:44 EDT

High10.15	Low9.76	Vol8.94M
Open10.09	D1 Closing10.09	Amplitude3.87%
Mkt Cap7.03B	Tradable Cap3.65B	Total Shares713.55M
T/O88.64M	T/O Rate2.41%	Tradable Shares370.56M
P/B1.35	ROE-14.64%	EPS-0.16
52wk High13.06	52wk Low9.76	P/E-63.28
Dividend0.00	Div.Yield0.00	ROA-11.62%

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"ROIV","market":"US","secType":"STK","nameCN":"Roivant Sciences Ltd.","latestPrice":9.85,"timestamp":1743537600000,"preClose":10.09,"halted":0,"volume":8938501,"hourTrading":{"tag":"盘后","latestPrice":9.85,"preClose":9.85,"latestTime":"18:44 EDT","volume":385543,"amount":3798207.2585,"timestamp":1743547441870},"delay":0,"floatShares":370555010,"shares":713549458,"eps":-0.155667,"marketStatus":"Closed","change":-0.24,"latestTime":"04-01 16:00:00 EDT","open":10.09,"high":10.145,"low":9.755,"amount":88637947.963422,"amplitude":0.038652,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.155667,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1743580800000},"marketStatusCode":5,"adr":0,"listingDate":1607403600000,"exchange":"NASDAQ","adjPreClose":10.09,"preHourTrading":{"tag":"盘前","latestPrice":10.02,"preClose":10.09,"latestTime":"09:27 EDT","volume":7146,"amount":72075.15626399999,"timestamp":1743514070034},"postHourTrading":{"tag":"盘后","latestPrice":9.85,"preClose":9.85,"latestTime":"18:44 EDT","volume":385543,"amount":3798207.2585,"timestamp":1743547441870},"volumeRatio":1.538356,"impliedVol":0.1645,"impliedVolPercentile":0.1434},"requestUrl":"/m/hq/s/ROIV/tweets","defaultTab":"tweets","newsList":[{"id":"2522374757","title":"Arbutus Biopharma Cuts Workforce by More Than Half, Hires New CFO in Exec Shuffle","url":"https://stock-news.laohu8.com/highlight/detail?id=2522374757","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522374757?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 19:56","pubTimestamp":1743076560,"startTime":"0","endTime":"0","summary":"Arbutus Biopharma is cutting its workforce by more than half as it looks to improve its financial and operational efficiency.The clinical-stage biopharmaceutical company said its board approved a workforce reduction of 57%, bringing its employee count down to 19. It also decided to exit its corporate headquarters in Warminster, Penn., and to discontinue in-house scientific research.Arbutus expects to incur a one-time restructuring charge between $11 million and $13 million in the first quarter.Chief Executive Lindsay Androski, who joined the company in February, said a core team will focus on advancing imdusiran into a Phase 2b trial.Arbutus also named Tuan Nguyen as chief financial officer, effective Friday, to succeed David Hastings. The company additionally announced the departure of J. Christopher Naftzger as general counsel and chief compliance officer as well as Karen Sims as chief medical officer.Nguyen most recently served as CFO of Kinevant Sciences, a subsidiary of Roivant Sc","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","ROIV","ABUS"],"gpt_icon":0},{"id":"2522860768","title":"Is Roivant Sciences Ltd. (NASDAQ:ROIV) One of The Best Stocks to Buy According to Billionaire David Einhorn?","url":"https://stock-news.laohu8.com/highlight/detail?id=2522860768","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522860768?lang=en_us&edition=full_marsco","pubTime":"2025-03-26 02:12","pubTimestamp":1742926370,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Best Stocks to Buy According to Billionaire David Einhorn. In this article, we are going to take a look at where Roivant Sciences Ltd.  stands against other best stocks to buy according to billionaire David Einhorn.David Einhorn is a highly regarded hedge fund manager, who co-foundedGreenlight Capitalin 1996. Einhorn shot to fame after he correctly forecasted the collapse of Lehman Brothers during the financial crisis. He graduated from Cornell University and garnered his skills in the hedge fund industry under the mentorship of Gary Siegler and Peter Collery at the SC Fundamental Value Fund.Due to his prowess in long/short equity strategies, David Einhorn is being tagged as one of the most successful hedge fund managers.To list the 10 Best Stocks to Buy According to Billionaire David Einhorn, we selected the top 10 stocks in Greenlight Capital’s portfolio as per its Q4 20","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/roivant-sciences-ltd-nasdaq-roiv-181250568.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":[".IXIC","TQQQ","TSYW.SI","IMVT","LU2210149790.SGD","GLRE","BK4588","BK4112","BK4585","MNQmain","LU2210150020.SGD","LU2095319765.USD","PSQ","IE00BGHQF748.EUR","ROIV","IE00B64PRP62.GBP","NVIW.SI","BK4007","QLD","SQQQ","IE00BKPKM429.USD","NDAQ","NQmain","BK4019","USJW.SI","BK4139","USAW.SI","IE00B3QW5Z07.USD","QID"],"gpt_icon":1},{"id":"2520578321","title":"Immunovant Ditches Seeking FDA Approval For Batoclimab For Two Autoimmune Disorders Despite Positive Phase 3 Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2520578321","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520578321?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 00:39","pubTimestamp":1742402340,"startTime":"0","endTime":"0","summary":"Wednesday, Immunovant,Inc.  released topline results from its Phase 3 study of batoclimab in myasthenia gravis  and initial results from Period 1 of its Phase 2b study in chronic inflammatory demyelinating polyneuropathy .Immunovant is a member of theRoivant Sciences Ltd. family of companies.In the Phase 3 MG study, batoclimab met its primary endpoint of mean change from baseline in Myasthenia Gravis Activities of Daily Living  score in acetylcholine receptor antibody positive  participants.Participants entering the study and randomized to 680mg of batoclimab given weekly by subcutaneous injection achieved a 5.6-point improvement  in MG-ADL at Week 12.In comparison, those randomized to 340mg of batoclimab given weekly by subcutaneous injection achieved a 4.7-point improvement .Initial batoclimab data in 73 patients pooled across all cohorts for the run-in Period 1 of the Phase 2b CIDP study demonstrated a 1.8 point improvement in aINCAT  at Week 12.An 84% responder rate  was observed a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/immunovant-ditches-seeking-fda-approval-163900373.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B7SZL793.SGD","BK4588","BK4007","MG","IE0031619046.USD","IMVT","ROIV","IE00B66KJ199.SGD","BK4123","BK4139","BK4585","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2520900531","title":"Roivant Sciences Ltd - Phase 3 Mg Study Meets Primary Endpoint With 5.6 Point Improvement","url":"https://stock-news.laohu8.com/highlight/detail?id=2520900531","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520900531?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 19:45","pubTimestamp":1742384700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250319:nTUA7LCRWL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ROIV","BK4007"],"gpt_icon":0},{"id":"2516637517","title":"Roivant Sciences Unit, Arbutus File Lawsuits Against Moderna for Alleged Patent Infringement","url":"https://stock-news.laohu8.com/highlight/detail?id=2516637517","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516637517?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 23:07","pubTimestamp":1741014467,"startTime":"0","endTime":"0","summary":"Roivant Sciences'  subsidiary Genevant Sciences and Arbutus Biopharma  said Monday they have filed five international lawsuits seeking to enforce patents protecting their lipid nanoparticle technology against infringement by Moderna and certain affiliates.The enforcement actions target alleged infringing activities in 30 countries, the two companies said. They are seeking monetary relief and injunctions against Spikevax and, where applicable, additional Moderna products that allegedly use the same technology, including mRESVIA.Lawsuits were filed in courts in Canada, Japan and Switzerland, while two were filed in the European Union's Unified Patent Court.The enforcement actions expand on the two companies' ongoing enforcement proceeding in the US District Court for the District of Delaware, seeking fair compensation for Moderna's alleged infringement of six US patents in the manufacture and sale of Spikevax. A jury trial is currently scheduled for September, they said.Moderna did not i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4568","ABUS","BK4139","BK4585","BK4532","BK4501","BK4588","BK4007","BK4551","BK4534","ROIV","BK4548","BK4533"],"gpt_icon":1},{"id":"2516313176","title":"Genevant: Seeking Monetary Relief, Injunctions Against Spikevax &, Where Applicable, Additional Products That Moderna Represented Use Same Lnp Tech","url":"https://stock-news.laohu8.com/highlight/detail?id=2516313176","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516313176?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 22:15","pubTimestamp":1741011309,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUA4YDVCV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4534","BK4588","ROIV","BK4533","ABUS","BK4568","BK4007","BK4585","MRNA","BK4551","BK4532","BK4501","BK4139","BK4548"],"gpt_icon":0},{"id":"2516631339","title":"Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2516631339","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516631339?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 22:15","pubTimestamp":1741011300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nTUA5GW9JG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ROIV","ABUS","BK4007"],"gpt_icon":0},{"id":"2516316566","title":"Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna","url":"https://stock-news.laohu8.com/highlight/detail?id=2516316566","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516316566?lang=en_us&edition=full_marsco","pubTime":"2025-03-03 22:15","pubTimestamp":1741011300,"startTime":"0","endTime":"0","summary":"BASEL, Switzerland and VANCOUVER, British Columbia and WARMINSTER, Pa., March 03, 2025  -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle  patent portfolio , and Arbutus Biopharma Corporation , a clinical-stage biopharmaceutical company focused on infectious disease, today filed five international lawsuits seeking to enforce patents protecting their innovative LNP technology against Moderna, Inc. and certain affiliates. Together, the enforcement actions target alleged infringing activities in 30 countries.Genevant and Arbutus are seeking monetary relief and injunctions against Spikevax and, where applicable, additional Moderna products that Moderna has represented use the same LNP technology, including mRESVIA.Where permitted to do so at this stage, Genevant and Arbutus submitted evidence from testing of commercial Moderna product samples sourced from the U.S. and Europe indicating that the samples contain LNPs fall","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/genevant-sciences-arbutus-biopharma-initiate-141500465.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ABUS","BK4007","ROIV","UPC"],"gpt_icon":0},{"id":"2514096269","title":"Early Warning Report Issued Pursuant to National Instrument 62‐103: Roivant Announces Resignation and Replacement of Arbutus Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2514096269","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514096269?lang=en_us&edition=full_marsco","pubTime":"2025-02-25 21:00","pubTimestamp":1740488400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250225:nTUA66NWKR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","BK4139","ROIV"],"gpt_icon":0},{"id":"1114746336","title":"Stock Track | Roivant Sciences Soars 5.27% After-Hours as Analysts Upgrade Financial Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=1114746336","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114746336?lang=en_us&edition=full_marsco","pubTime":"2025-02-13 06:16","pubTimestamp":1739398594,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.  stock surged 5.27% in after-hours trading on Wednesday, following analysts' significant upgrades to their revenue and earnings estimates for the company.Analysts covering Roivant Sciences revised their consensus estimates, projecting $43 million in revenue for the company in 2026, a sharp increase from their previous forecast of $36 million. Additionally, they reduced their loss estimates for the next year, now expecting losses of $1.17 per share instead of the earlier pro","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Stock Track | Roivant Sciences Soars 5.27% After-Hours as Analysts Upgrade Financial Forecasts","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ROIV"],"gpt_icon":1},{"id":"2511658162","title":"Roivant Sciences Insiders Sold US$52m Of Shares Suggesting Hesitancy","url":"https://stock-news.laohu8.com/highlight/detail?id=2511658162","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511658162?lang=en_us&edition=full_marsco","pubTime":"2025-02-12 19:36","pubTimestamp":1739360176,"startTime":"0","endTime":"0","summary":"Many Roivant Sciences Ltd. ( NASDAQ:ROIV ) insiders ditched their stock over the past year, which may be of interest to...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-roiv/roivant-sciences/news/roivant-sciences-insiders-sold-us52m-of-shares-suggesting-he","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","BK4007","ROIV"],"gpt_icon":0},{"id":"2510606327","title":"News Flash: Analysts Just Made A Captivating Upgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) Forecasts","url":"https://stock-news.laohu8.com/highlight/detail?id=2510606327","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510606327?lang=en_us&edition=full_marsco","pubTime":"2025-02-12 19:03","pubTimestamp":1739358188,"startTime":"0","endTime":"0","summary":"Celebrations may be in order for Roivant Sciences Ltd.  shareholders, with the analysts delivering a significant upgrade to their statutory estimates for the company. The revenue forecast for next year has experienced a facelift, with the analysts now much more optimistic on its sales pipeline.Following the latest upgrade, the five analysts covering Roivant Sciences provided consensus estimates of US$43m revenue in 2026, which would reflect a painful 65% decline on its sales over the past 12 months. Per-share losses are expected to see a sharp uptick, reaching US$1.17. However, before this estimates update, the consensus had been expecting revenues of US$36m and US$1.19 per share in losses. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to next year's revenue estimates, while at the same time reducing their loss estimates.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/news-flash-analysts-just-made-110308191.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ROIV","NDAQ",".IXIC"],"gpt_icon":0},{"id":"2510337039","title":"Roivant Sciences Price Target Maintained With a $18.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2510337039","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510337039?lang=en_us&edition=full_marsco","pubTime":"2025-02-12 01:34","pubTimestamp":1739295240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ROIV/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 11, 2025 12:34 ET (17:34 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"gpt_icon":0},{"id":"2510338043","title":"Roivant Sciences price target lowered to $12 from $13 at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2510338043","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510338043?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 23:00","pubTimestamp":1739286039,"startTime":"0","endTime":"0","summary":"BofA lowered the firm’s price target on Roivant Sciences (ROIV) to $12 from $13 and keeps a Neutral rating on the shares. The fiscal Q3 call was “r...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-lowered-to-12-from-13-at-bofa?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/roivant-sciences-price-target-lowered-to-12-from-13-at-bofa?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ROIV","BK4007","BK4139"],"gpt_icon":0},{"id":"2510806777","title":"Roivant Sciences (ROIV) Receives a Hold from Bank of America Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2510806777","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510806777?lang=en_us&edition=full_marsco","pubTime":"2025-02-11 18:15","pubTimestamp":1739268920,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Chi Meng Fong from Bank of America Securities reiterated a Hold rating on Roivant Sciences (ROIV – Research Report)...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/roivant-sciences-roiv-receives-a-hold-from-bank-of-america-securities?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/roivant-sciences-roiv-receives-a-hold-from-bank-of-america-securities?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BZ1G4Q59.USD","LU1496350502.SGD","BK4534","LU0149725797.USD","LU0170899867.USD","LU0053666078.USD","LU0208291251.USD","LU0256863902.USD","LU0477156797.USD","LU2133065610.SGD","BAC","LU0640476718.USD","ROIV","LU1883839398.USD","LU1880398554.USD","LU0256863811.USD","LU0868494617.USD","LU2129689605.HKD","LU1496350171.SGD","IE00B7SZLL34.SGD","LU0320765489.SGD","LU0306807586.USD","LU0980610538.SGD","LU2129689514.USD","IE00B19Z3B42.SGD","LU0971096721.USD","LU1074936037.SGD","LU1363072403.SGD","LU1718418525.SGD","BK4581","LU1267930227.SGD","LU1201861249.SGD","LU0130518102.USD","LU1366192091.USD","IE0002270589.USD","LU0070302665.USD","LU0234572021.USD","IE00BKVL7J92.USD","LU0321505868.SGD","LU1201861165.SGD","BK4007","LU1668664300.SGD","BK4588","LU0648000940.SGD","IE00BLSP4239.USD","LU1791807156.HKD","BK4585","LU0306806265.USD","LU1894683348.USD","IE00B1BXHZ80.USD"],"gpt_icon":0},{"id":"1130003008","title":"Stock Track | Roivant Sciences Soars 5.51% Pre-Market on Promising Pipeline and Earnings Surprise","url":"https://stock-news.laohu8.com/highlight/detail?id=1130003008","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130003008?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 22:32","pubTimestamp":1739197941,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd.  stock surged 5.51% in pre-market trading on Monday, following the release of its third-quarter fiscal 2024 financial results and a promising update on its product pipeline.Despite reporting lower earnings and revenue for the quarter, Roivant Sciences managed to beat analysts' expectations for its income from operations. The biopharmaceutical company reported a net income of $118.075 million for the quarter, driven by strong performance from its pipeline candidates and stra","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ROIV"],"gpt_icon":1},{"id":"2510868021","title":"Roivant Sciences Ltd reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2510868021","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510868021?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 22:31","pubTimestamp":1739197903,"startTime":"0","endTime":"0","summary":"Roivant Sciences Ltd reports results for the quarter ended December 31 - Earnings SummaryRoivant Sciences Ltd ROIV.OQ reported quarterly adjusted earnings of 23 cents per share for the quarter ended D","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250210:nL8N3P11GV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"gpt_icon":0},{"id":"2510850272","title":"Sector Update: Health Care Stocks Flat to Edging Higher Pre-Bell Monday","url":"https://stock-news.laohu8.com/highlight/detail?id=2510850272","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510850272?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 22:10","pubTimestamp":1739196622,"startTime":"0","endTime":"0","summary":"Health care stocks were flat to edging higher pre-bell Monday as the iShares Biotechnology ETF  was inactive and the Health Care Select Sector SPDR Fund  was up 0.2% recently.Pliant Therapeutics  shares declined by nearly 61% after the company said it has suspended enrollment and treatment in a phase 2b trial of bexotegrast for idiopathic pulmonary fibrosis following a recommendation from the trial's data safety monitoring board.Roivant Sciences  shares were up nearly 6% even after the company reported lower fiscal Q3 earnings and revenue.DocGo  shares rose past 3% after the company said it has acquired PTI Health to add mobile phlebotomy lab services to its portfolio.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4588","BK4139","BK4581","XLV","ROIV","BK4585","PLRX","IBB","BK4196","DCGO"],"gpt_icon":0},{"id":"2510564218","title":"Roivant Sciences Fiscal Q3 Earnings, Revenue Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2510564218","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510564218?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 20:16","pubTimestamp":1739189787,"startTime":"0","endTime":"0","summary":"Roivant Sciences  reported fiscal Q3 earnings Monday of $0.23 per diluted share, down from $6.03 a year earlier.Four analysts polled by FactSet expected a loss of $0.31.Revenue for the quarter ended Dec. 31 was $9 million, compared with $15.6 million a year earlier.Analysts surveyed by FactSet expected $5 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ROIV"],"gpt_icon":0},{"id":"2510856496","title":"Roivant Sciences Q3 Adj $(0.20) Beats $(0.28) Estimate, Sales $9.02M Miss $15.99M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2510856496","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510856496?lang=en_us&edition=full_marsco","pubTime":"2025-02-10 20:09","pubTimestamp":1739189368,"startTime":"0","endTime":"0","summary":"Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.28) by 28.57 percent. This is a 4.76 percent increase over losses of $(0.21) per share from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/02/43588712/roivant-sciences-q3-adj-0-20-beats-0-28-estimate-sales-9-02m-miss-15-99m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Roivant Sciences Q3 Adj $(0.20) Beats $(0.28) Estimate, Sales $9.02M Miss $15.99M Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.roivant.com","stockEarnings":[{"period":"1week","weight":-0.0683},{"period":"1month","weight":-0.0605},{"period":"3month","weight":-0.1471},{"period":"6month","weight":-0.1055},{"period":"1year","weight":-0.0427},{"period":"ytd","weight":-0.1471}],"compareEarnings":[{"period":"1week","weight":-0.0256},{"period":"1month","weight":-0.0586},{"period":"3month","weight":-0.0455},{"period":"6month","weight":-0.0166},{"period":"1year","weight":0.0694},{"period":"ytd","weight":-0.0455}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.085134},{"month":2,"riseRate":0.2,"avgChangeRate":-0.004587},{"month":3,"riseRate":0,"avgChangeRate":-0.096551},{"month":4,"riseRate":0.75,"avgChangeRate":-0.013041},{"month":5,"riseRate":0.5,"avgChangeRate":0.053964},{"month":6,"riseRate":0.75,"avgChangeRate":0.012477},{"month":7,"riseRate":0.75,"avgChangeRate":0.048723},{"month":8,"riseRate":0.5,"avgChangeRate":-0.002132},{"month":9,"riseRate":0.25,"avgChangeRate":-0.05068},{"month":10,"riseRate":0.5,"avgChangeRate":0.046516},{"month":11,"riseRate":0.75,"avgChangeRate":0.021182},{"month":12,"riseRate":0.75,"avgChangeRate":0.279121}],"exchange":"NASDAQ","name":"Roivant Sciences Ltd.","nameEN":"Roivant Sciences Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Roivant Sciences Ltd.,ROIV,Roivant Sciences Ltd.股票,Roivant Sciences Ltd.股票老虎,Roivant Sciences Ltd.股票老虎国际,Roivant Sciences Ltd.行情,Roivant Sciences Ltd.股票行情,Roivant Sciences Ltd.股价,Roivant Sciences Ltd.股市,Roivant Sciences Ltd.股票价格,Roivant Sciences Ltd.股票交易,Roivant Sciences Ltd.股票购买,Roivant Sciences Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Roivant Sciences Ltd.(ROIV),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Roivant Sciences Ltd.(ROIV) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction